The affirmance removes a patent overhang on Sanofi's pneumococcal vaccine business. With the IPR final, Sanofi faces no immediate patent challenge from Pfizer on these claims. Monitor for any potential Supreme Court cert petition, though unlikely given the nonprecedential nature. The ruling is a modest positive for SNY's vaccine segment.
SNY drugs
SNY drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 3 $42.95entry
- T+1 · 4mo ago −0.63%α −2.43% · $42.68
- T+5 · 3mo ago +1.23%α −0.79% · $43.48
- T+20 · 3mo ago +3.28%α +2.04% · $44.36
- T+60 · 21d ago −2.68%α −4.46% · $41.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The Federal Circuit affirmed the PTAB's denial of Pfizer's motion to amend patent claims in three IPR proceedings, ruling that Pfizer's proposed substitute claims for pneumococcal vaccine patent U.S. 9,492,559 would have been obvious. This is a final win for Sanofi, removing a potential patent infringement threat to its pneumococcal vaccine franchise.
Court Ruling Details
Key Facts
- Federal Circuit affirmed PTAB's obviousness finding for Pfizer's proposed substitute claims 48 and 49
- Sanofi (appellee) successfully defended against Pfizer's attempt to amend patent claims covering pneumococcal vaccine compositions
- Ruling is nonprecedential but final, with no further appeal available
- Patent U.S. 9,492,559 covers immunogenic compositions with specific S. pneumoniae serotypes conjugated to CRM197
Financial Impact
No damages awarded; ruling eliminates potential patent infringement liability for Sanofi's pneumococcal vaccines, but financial impact is not quantified in the opinion
Risk Factors
- Pfizer could theoretically seek certiorari, but the nonprecedential disposition and lack of novel legal issues make this unlikely
- Other patent challenges to Sanofi's pneumococcal vaccine portfolio may still exist
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 court opinions.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3479514c72-SNY |
| COURT-RULING Data (Synthetic) | court-6391b880d2-SNY |
| COURT-RULING Data (Synthetic) | court-6a6fb94ccc-SNY |
Track record
15 reports on SNY
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +7.69% at T+60 after the Aug 17, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $47.47 to $48.43 Now $48.39 +1.94% ▲ +2.02% +2.94% vs SPY
- Oct 30, 202617d ago 6-K Bullish 6/10 Entry $44.34 to $47.04 Now $48.39 +9.13% ▲ +6.09% +8.79% vs SPY
- Oct 26, 202621d ago SC 13G/A Neutral 2/10 Entry $41.89 to $45.33 Now $48.39 +15.52% ▲ +8.21% +10.20% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $41.79 to $44.34 Now $48.39 +15.79% ▲ +6.10% +7.36% vs SPY
- Oct 1, 20266w ago 6-K Mixed 5/10 Entry $40.67 to $40.23 Now $48.39 +18.98% ▼ −1.08% −2.38% vs SPY
- Sep 17, 20268w ago 6-K Neutral 4/10 Entry $43.14 to $40.94 Now $48.39 +12.17% ▼ −5.10% −5.95% vs SPY
- Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $44.37 to $42.85 Now $48.39 +9.06% ▼ −3.43% −3.51% vs SPY
- Aug 17, 202613w ago Court Ruling Bullish 4/10 Entry $44.97 to $46.02 Now $48.39 +7.61% ▲ +2.33% +2.54% vs SPY
- Aug 12, 202613w ago Court Ruling Neutral 2/10 Entry $43.78 to $45.15 Now $48.39 +10.53% ▲ +3.13% +5.09% vs SPY
- Jul 31, 202615w ago Court Ruling Bullish 5/10 Viewing Entry $42.95 to $43.48 Now $48.39 +12.67% ▲ +1.23% −0.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers